Passage Bio Inc (PASG) — Strategic Asset Allocation Index

Latest as of June 2023: 13.4%

Passage Bio Inc (PASG) has a Strategic Asset Allocation Index of 13.4% as of June 2023. Strategic assets (PP&E of $20.23 Million plus long-term investments of $-) total $20.23 Million, measured against net assets of $150.41 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check asset resilience ratio of Passage Bio Inc to evaluate the company's liquid asset resilience ratio.

SAAI

13.4%
Strategic Assets / Net Assets

Strategic Assets

$20.23 Million
PP&E + LT Investments

PP&E

$20.23 Million
USD

Net Assets

$150.41 Million
USD

Passage Bio Inc Strategic Asset Allocation Index (2019–2022)

This chart shows how Passage Bio Inc's Strategic Asset Allocation Index has evolved across 4 annual periods from 2019 to 2022. As of June 2023, the index stands at 13.4%, representing strategic assets of $20.23 Million against net assets of $150.41 Million USD. See financial agility of Passage Bio Inc to measure the company's free cash flow as a share of total liabilities.

Annual Strategic Asset Allocation Index for Passage Bio Inc (2019–2022)

The table below presents the year-by-year Strategic Asset Allocation Index for Passage Bio Inc from 2019 to 2022, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Passage Bio Inc market capitalisation.

Year SAAI Strategic Assets (USD) PP&E LT Investments Net Assets Change (pp)
2022 11.2% $22.52 Million $22.52 Million $- $201.37 Million ▲ +3.7 pp
2021 7.5% $23.81 Million $23.81 Million $- $318.66 Million ▲ +6.6 pp
2020 0.9% $2.79 Million $2.79 Million $- $304.71 Million ▲ +0.3 pp
2019 0.6% $1.09 Million $1.09 Million $- $174.35 Million
pp = percentage points